Braga Anna Caroline, Gromicho Marta, Pinto Susana, de Carvalho Mamede, Henning Franclo
Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal; Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa-Norte, Lisbon, Portugal.
J Neurol Sci. 2020 Jul 15;414:116857. doi: 10.1016/j.jns.2020.116857. Epub 2020 Apr 20.
Data on the epidemiological and clinical aspects of ALS originate from a few world regions, and very little is known about ALS in low and middle-income countries, in particular Sub-Saharan Africa. This brief report attempts to provide preliminary perspectives on the clinical features and management of ALS in Sub-Saharan Africa by comparing two cohorts from South Africa (SA) and Portugal.
The study was performed at ALS clinics at Tygerberg Hospital, Cape Town, South Africa, and Centro Hospitalar Universitário Lisboa-Norte, Portugal. We included all patients diagnosed over a four-year period, and collected demographic and clinical data at diagnosis, longitudinal data on disease progression and management over 12 months, and mortality rates at 12 and 24 months.
SA patients were younger and had a higher rate of spinal-onset disease than their Portuguese counterparts. During the 12-month follow-up, NIV was introduced in half of Portuguese patients, but only a quarter of SA patients. Parenteral nutrition was introduced in less than 10% of patients in both groups. No SA patients used riluzole, while 100% of Portuguese patients did. Mortality rates were significantly higher in the SA cohort at both 12 months (35% vs 16%; p < .0001) and 24 months (63% vs 39%; p < .0001).
Although SA patients were younger and more likely to have spinal-onset disease, mortality was higher in this cohort. There was a significant difference in utilisation of NIV and riluzole between the two cohorts, both of which may influence survival.
肌萎缩侧索硬化症(ALS)的流行病学和临床方面的数据来自世界上少数几个地区,而关于低收入和中等收入国家,特别是撒哈拉以南非洲地区的ALS情况,人们了解甚少。本简要报告试图通过比较来自南非(SA)和葡萄牙的两个队列,对撒哈拉以南非洲地区ALS的临床特征和管理提供初步见解。
该研究在南非开普敦泰格堡医院和葡萄牙里斯本北部大学医院中心的ALS诊所进行。我们纳入了在四年期间确诊的所有患者,并收集了诊断时的人口统计学和临床数据、12个月内疾病进展和管理的纵向数据,以及12个月和24个月时的死亡率。
SA患者比葡萄牙患者更年轻,且脊柱起病疾病的发生率更高。在12个月的随访期间,一半的葡萄牙患者开始使用无创通气(NIV),但只有四分之一的SA患者使用。两组中不到10%的患者采用了肠外营养。没有SA患者使用利鲁唑,而100%的葡萄牙患者使用了。SA队列在12个月(35%对16%;p<0.0001)和24个月(63%对39%;p<0.0001)时的死亡率均显著更高。
尽管SA患者更年轻,且更有可能患有脊柱起病疾病,但该队列的死亡率更高。两个队列在NIV和利鲁唑的使用上存在显著差异,这两者都可能影响生存。